Skip to content

The Anorectal Function and QoL of Patients Receiving Transrectal NOSE Via Rigid TAMIS Platform in Minimal Invasive Colon Surgery

A Prospective, Multi-Center, Single-Arm, Open-Label Study to Analyze Anorectal Function and Quality of Life in Patients Undergoing Minimally Invasive Colectomy With Transrectal Natural Orifice Specimen Extraction (NOSE) Using a Rigid Transanal Minimally Invasive Surgery (TAMIS) Platform

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07653607
Enrollment
57
Registered
2026-06-17
Start date
2026-06-01
Completion date
2029-07-31
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colon Surgery, Minimal Invasive Surgery

Brief summary

The primary objective of this study is to prospectively determine and precisely estimate the incidence of Internal Anal Sphincter (IAS) Injury at 12 months following colectomy with Transrectal NOSE.

Interventions

PROCEDUREPre-op and post-op anorectal function and quality of life evaluation

Pre-op and post-op anorectal function, rectal ultrasound and quality of life evaluation via questionaires

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female, aged above 18 years, inclusive. 2. Patients scheduled for an elective laparoscopic or robotic-assisted colectomy above sigmoid colon. 3. Deemed a suitable candidate for the Transrectal NOSE procedure by the treating surgical team, based on tumor size (generally, largest diameter \< 4 cm), tumor T stage(1-3), location, and patient anatomy. 4. American Society of Anesthesiologists (ASA) physical status classification of I, II, or III. 5. Able to understand the purpose, procedures, potential risks, and benefits of the study and willing to provide written informed consent, as approved by the Institutional Review Board (IRB). 6. Willing and able to comply with all scheduled follow-up visits and assessment procedures outlined in the protocol.

Exclusion criteria

1. Pre-existing moderate-to-severe fecal incontinence, defined as a Wexner incontinence score \> 8. 2. History of any prior anal surgery (e.g., sphincteroplasty, artificial sphincter implantation, fistulotomy), major pelvic surgery (e.g., hysterectomy, radical prostatectomy), or pelvic radiation therapy. 3. Confirmed diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis). 4. The planned surgical procedure requires a protective stoma. 5. Uncorrectable coagulopathy identified on preoperative assessment. 6. Known neurological condition affecting bowel control (e.g., spinal cord injury, multiple sclerosis, significant post-stroke deficits). 7. Cognitive impairment, severe psychiatric illness, or other condition that would interfere with reliable completion of questionnaires or compliance with the protocol. 8. Currently pregnant, breastfeeding, or planning to become pregnant during the study period. 9. Concurrent participation in another interventional clinical trial that could potentially interfere with the study outcomes. 10. Any other condition which, in the professional opinion of the investigator, makes the subject unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
The incidence of Internal Anal Sphincter (IAS) injury12 months post-surgery.

Secondary

MeasureTime frameDescription
Change from baseline in Wexner score.12 months post surgeryThe change from baseline in the total Wexner Incontinence Score (range 0-20) at each follow-up visit. A higher score means worse outcome.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026